In summary, our study demonstrates that genetically proxied inhibition of PCSK9 is strongly associated with a lower risk of overall and early-onset prostate cancer, potentially through a mechanism involving the lowering of Lp(a) levels. The gene discussed is PCSK9; the disease is prostate cancer.